Dramatic Response to First Line Single Agent Pembrolizumab in Anaplastic Thyroid Carcinoma

Figure 2

Chest CT after 3 cycles of pembrolizumab showing marked regression of primary tumor (a), lung metastases and (b), lymph nodes (c).